Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Saved in:
| Title: | Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease. |
|---|---|
| Authors: | Zimmer JA; Eli Lilly and Company Indianapolis Indiana USA., Shcherbinin S; Eli Lilly and Company Indianapolis Indiana USA., Devous MD Sr; Eli Lilly and Company Indianapolis Indiana USA., Bragg SM; Eli Lilly and Company Indianapolis Indiana USA., Selzler KJ; Eli Lilly and Company Indianapolis Indiana USA., Wessels AM; Eli Lilly and Company Indianapolis Indiana USA., Shering C; AstraZeneca, Neuroscience Biopharmaceuticals R&D Boston Massachusetts USA., Mullen J; AstraZeneca, Neuroscience Biopharmaceuticals R&D Boston Massachusetts USA., Landry J; Eli Lilly and Company Indianapolis Indiana USA., Andersen SW; Eli Lilly and Company Indianapolis Indiana USA., Downing AM; Eli Lilly and Company Indianapolis Indiana USA., Fleisher AS; Eli Lilly and Company Indianapolis Indiana USA., Svaldi DO; Eli Lilly and Company Indianapolis Indiana USA., Sims JR; Eli Lilly and Company Indianapolis Indiana USA. |
| Source: | Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2021 Feb 14; Vol. 7 (1), pp. e12123. Date of Electronic Publication: 2021 Feb 14 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-8737 (Electronic) Linking ISSN: 23528737 NLM ISO Abbreviation: Alzheimers Dement (N Y) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
